Xencor

$39.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.63 (+1.62%) As of 6:19 PM UTC today

Why Robinhood?

You can buy or sell Xencor and other stocks, options, and ETFs commission-free!

About XNCR

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA. The listed name for XNCR is Xencor, Inc. Common Stock.

CEO
Bassil I. Dahiyat
Employees
166
Headquarters
Monrovia, California
Founded
1997
Market Cap
2.27B
Price-Earnings Ratio
Dividend Yield
Average Volume
262.89K
High Today
$39.58
Low Today
$38.27
Open Price
$38.81
Volume
68.96K
52 Week High
$43.90
52 Week Low
$19.35

Collections

XNCR Earnings

-$0.61
$0.05
$0.72
$1.38
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 24, After Hours

You May Also Like